ReviewCells2025
Targeting Regulated Cell Death Pathways in COPD: Mechanisms and Therapeutic Strategies.
Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting pyroptosis to treat aortic aneurysms: From mechanism to drug discovery (Review).International journal of molecular medicine · 2026Review
- Mitochondrial dysfunction and the regulatory cell death crosstalk network in chronic obstructive pulmonary disease: from oxidative stress mechanisms to targeted therapeutic strategies.Frontiers in immunology · 2026Review
- The role of programmed cell death in chronic obstructive pulmonary disease: from pathogenesis to treatment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease defined by persistent airflow limitation, chronic inflammation, and ongoing airway remodeling, and poses a substantial global health challenge. Despite its clinical significance, the underlying cellular mechanisms remain poorly defined. Regulated cell death (RCD) incorporates various kinds of cell death that are typically regulated by specific molecular pathways. Numerous new kinds of RCD have been identified outside of the traditional apoptotic pathway, like necroptosis, pyroptosis, ferroptosis, autophagy, cuproptosis, and parthanatos. To date, there is growing evidence indicating that these pathways participate in the regulation of COPD development. However, their specific roles and therapeutic relevance remain poorly understood. In this review, we discuss a summary of the molecular mechanisms by which RCD pathways influence the onset and advancement of COPD. Additionally, the therapeutic benefits of agents that target these cell death pathways in COPD treatment were described. By integrating current insights, this review aims to broaden our knowledge of the pathophysiology of COPD and offer novel approaches to treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.